Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 7672048, 9 pages
http://dx.doi.org/10.1155/2016/7672048
Research Article

Serum Cytokines in Young Pediatric Patients with Congenital Cardiac Shunts and Altered Pulmonary Hemodynamics

1Heart Institute, University of São Paulo School of Medicine, São Paulo, SP, Brazil
2Pró-Sangue Foundation, São Paulo, SP, Brazil
3Stanford University School of Medicine, Stanford, CA, USA

Received 19 May 2016; Accepted 7 August 2016

Academic Editor: Dianne Cooper

Copyright © 2016 Leína Zorzanelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Rabinovitch, C. Guignabert, M. Humbert, and M. R. Nicolls, “Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension,” Circulation Research, vol. 115, no. 1, pp. 165–175, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Dorfmüller, F. Perros, K. Balabanian, and M. Humbert, “Inflammation in pulmonary arterial hypertension,” European Respiratory Journal, vol. 22, no. 2, pp. 358–363, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. M. R. Nicolls, L. Taraseviciene-Stewart, P. R. Rai, D. B. Badesch, and N. F. Voelkel, “Autoimmunity and pulmonary hypertension: a perspective,” European Respiratory Journal, vol. 26, no. 6, pp. 1110–1118, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Perros, P. Dorfmüller, D. Montani et al., “Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 3, pp. 311–321, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. R. F. A. Pinto, M. D. L. Higuchi, and V. D. Aiello, “Decreased numbers of T-lymphocytes and predominance of recently recruited macrophages in the walls of peripheral pulmonary arteries from 26 patients with pulmonary hypertension secondary to congenital cardiac shunts,” Cardiovascular Pathology, vol. 13, no. 5, pp. 268–275, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Hall, P. Brogan, S. G. Haworth, and N. Klein, “Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in children,” Thorax, vol. 64, no. 9, pp. 778–783, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Brun, H. Holmstrøm, E. Thaulow et al., “Patients with pulmonary hypertension related to congenital systemic-to-pulmonary shunts are characterized by inflammation involving endothelial cell activation and platelet-mediated inflammation,” Congenital Heart Disease, vol. 4, no. 3, pp. 153–159, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Sungprem, A. Khongphatthanayothin, P. Kiettisanpipop, P. Chotivitayatarakorn, Y. Poovorawan, and P. Lertsapcharoen, “Serum level of soluble intercellular adhesion molecule-1 correlates with pulmonary arterial pressure in children with congenital heart disease,” Pediatric Cardiology, vol. 30, no. 4, pp. 472–476, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Duncan, B. D. Wagner, K. Murray et al., “Circulating cytokines and growth factors in pediatric pulmonary hypertension,” Mediators of Inflammation, vol. 2012, Article ID 143428, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. U. Krishnan and E. B. Rosenzweig, “Pulmonary arterial hypertension associated with congenital heart disease,” Clinics in Chest Medicine, vol. 34, no. 4, pp. 707–717, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Zhang, M. Shen, M. Xu et al., “Role of macrophage migration inhibitory factor in the proliferation of smooth muscle cell in pulmonary hypertension,” Mediators of Inflammation, vol. 2012, Article ID 840737, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Daley, C. Emson, C. Guignabert et al., “Pulmonary arterial remodeling induced by a Th2 immune response,” The Journal of Experimental Medicine, vol. 205, no. 2, pp. 361–372, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Lindberg, A. K. Olsson, P. Jögi, and C. Jonmarker, “How common is severe pulmonary hypertension after pediatric cardiac surgery?” Journal of Thoracic and Cardiovascular Surgery, vol. 123, no. 6, pp. 1155–1163, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. K. L. Brown, D. A. Ridout, A. P. Goldman, A. Hoskote, and D. J. Penny, “Risk factors for long intensive care unit stay after cardiopulmonary bypass in children,” Critical Care Medicine, vol. 31, no. 1, pp. 28–33, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. I. R. Rivera, M. A. Mendonça, J. L. Andrade et al., “Pulmonary venous flow index as a predictor of pulmonary vascular resistance variability in congenital heart disease with increased pulmonary flow: a comparative study before and after oxygen inhalation,” Echocardiography, vol. 30, no. 8, pp. 952–960, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. T. H. Laird, S. A. Stayer, S. M. Rivenes et al., “Pulmonary-to-systemic blood flow ratio effects of sevoflurane, isoflurane, halothane, and fentanyl/midazolam with 100% oxygen in children with congenital heart disease,” Anesthesia & Analgesia, vol. 95, no. 5, pp. 1200–1206, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. J. L. Wilkinson, “Haemodynamic calculations in the catheter laboratory,” Heart, vol. 85, no. 1, pp. 113–120, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Heath and J. E. Edwards, “The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects,” Circulation, vol. 18, no. 4, part 1, pp. 533–547, 1958. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Kiss, K. Kovacs, A. Komocsi et al., “Novel mechanisms of sildenafil in pulmonary hypertension involving cytokines/chemokines, MAP kinases and Akt,” PLoS ONE, vol. 9, no. 8, Article ID e104890, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. A. A. Lopes, R. J. Barst, S. G. Haworth et al., “Repair of congenital heart disease with associated pulmonary hypertension in children: what are the minimal investigative procedures? Consensus statement from the Congenital Heart Disease and Pediatric Task Forces, Pulmonary Vascular Research Institute (PVRI),” Pulmonary Circulation, vol. 4, no. 2, pp. 330–341, 2014. View at Publisher · View at Google Scholar
  21. C. Weber, S. Kraemer, M. Drechsler et al., “Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 42, pp. 16278–16283, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Bernhagen, R. Krohn, H. Lue et al., “MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment,” Nature Medicine, vol. 13, no. 5, pp. 587–596, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Zernecke, J. Bernhagen, and C. Weber, “Macrophage migration inhibitory factor in cardiovascular disease,” Circulation, vol. 117, no. 12, pp. 1594–1602, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Tu, A. Huertas, M. Le Hiress et al., “MIF/CD74-dependent interleukin-6 and monocyte chemoattractant protein-1 secretion by pulmonary endothelial cells in idiopathic pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 187, Article ID A1739, 2013. View at Google Scholar
  25. M. Le Hiress, L. Tu, N. Ricard et al., “Proinflammatory signature of the dysfunctional endothelium in pulmonary hypertension. Role of the macrophage migration inhibitory factor/CD74 complex,” American Journal of Respiratory and Critical Care Medicine, vol. 192, no. 8, pp. 983–997, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. J. C. Kovacic, R. Gupta, A. C. Lee et al., “Stat3-dependent acute Rantes production in vascular smooth muscle cells modulates inflammation following arterial injury in mice,” The Journal of Clinical Investigation, vol. 120, no. 1, pp. 303–314, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. T. P. Mikolajczyk, R. Nosalski, P. Szczepaniak et al., “Role of chemokine RANTES in the regulation of perivascular inflammation, T-cell accumulation, and vascular dysfunction in hypertension,” The FASEB Journal, vol. 30, no. 5, pp. 1987–1999, 2016. View at Publisher · View at Google Scholar
  28. T. M. Thompson, P. L. Roddam, L. M. Harrison, J. A. Aitken, and J. P. DeVincenzo, “Viral specific factors contribute to clinical respiratory syncytial virus disease severity differences in infants,” Clinical Microbiology, vol. 4, no. 3, article 206, 2015. View at Publisher · View at Google Scholar
  29. H. Huang, L. Zhang, R. Liu et al., “Abstract 15110: the interleukin (IL)-16 gene polymorphisms and risk of coronary artery disease in Chinese Han population,” Circulation, vol. 124, Article ID A15110, 2011. View at Google Scholar
  30. S. L. Park, B. Hwang, S.-Y. Lee et al., “p21WAF1 is required for interleukin-16-induced migration and invasion of vascular smooth muscle cells via the p38MAPK/Sp-1/MMP-9 pathway,” PLoS ONE, vol. 10, no. 11, Article ID e0142153, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Rabinovitch, J. F. Keane, W. I. Norwood, A. R. Castaneda, and L. Reid, “Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects,” Circulation, vol. 69, no. 4, pp. 655–667, 1984. View at Publisher · View at Google Scholar · View at Scopus
  32. M. E. Yeager, C. M. Nguyen, D. D. Belchenko et al., “Circulating fibrocytes are increased in children and young adults with pulmonary hypertension,” European Respiratory Journal, vol. 39, no. 1, pp. 104–111, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Das, J. E. Moss, E. Robinson et al., “Role of macrophage migration inhibitory factor in the Th2 immune response to epicutaneous sensitization,” Journal of Clinical Immunology, vol. 31, no. 4, pp. 666–680, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. M. R. Kim, R. Manoukian, R. Yeh et al., “Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production,” Blood, vol. 100, no. 7, pp. 2330–2340, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Daley, C. Emson, C. Guignabert et al., “Pulmonary arterial remodeling induced by a Th2 immune response,” Journal of Experimental Medicine, vol. 205, no. 2, pp. 361–372, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Caunt, L. Hu, T. Tang, P. C. Brooks, S. Ibrahim, and S. Karpatkin, “Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis,” Cancer Research, vol. 66, no. 8, pp. 4125–4132, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Rabinovitch, S. G. Haworth, A. R. Castaneda, A. S. Nadas, and L. M. Reid, “Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease,” Circulation, vol. 58, no. 6, pp. 1107–1122, 1978. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Ide, T. Hirase, A. Nishimoto-Hazuku, Y. Ikeda, and K. Node, “Angiotensin II increases expression of IP-10 and the renin-angiotensin system in endothelial cells,” Hypertension Research, vol. 31, no. 6, pp. 1257–1267, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. P. M. George, E. Oliver, P. Dorfmuller et al., “Evidence for the involvement of type I interferon in pulmonary arterial hypertension,” Circulation Research, vol. 114, no. 4, pp. 677–688, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. G. A. Heresi, M. Aytekin, J. Newman, and R. A. Dweik, “CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival,” Lung, vol. 188, no. 3, pp. 191–197, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Zabini, A. Heinemann, V. Foris et al., “Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients,” European Respiratory Journal, vol. 44, no. 4, pp. 951–962, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. V. R. Placencio and Y. A. DeClerck, “Plasminogen activator inhibitor-1 in cancer: rationale and insight for future therapeutic testing,” Cancer Research, vol. 75, no. 15, pp. 2969–2974, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. M. D. Seferovic and M. B. Gupta, “Increased umbilical cord PAI-1 levels in placental insufficiency are associated with fetal hypoxia and angiogenesis,” Disease Markers, vol. 2016, Article ID 7124186, 13 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  44. F. M. Kouri, M. A. Queisser, M. Königshoff et al., “Plasminogen activator inhibitor type 1 inhibits smooth muscle cell proliferation in pulmonary arterial hypertension,” International Journal of Biochemistry and Cell Biology, vol. 40, no. 9, pp. 1872–1882, 2008. View at Publisher · View at Google Scholar · View at Scopus